アンチセンス＆RNAi治療市場レポート：技術、投与経路、用途、地域別、2024～2032年

世界のアンチセンス＆RNAi治療市場規模は2023年に17億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに32億米ドルに達し、2024～2032年の間に7.25％の成長率（CAGR）を示すと予測しています。同市場は、革新的な治療法を必要とする遺伝性疾患や慢性疾患の世界の蔓延の増加、新治療法の承認と商業化を促進するための主要市場全体での支持的な規制環境、ドラッグデリバリーシステムにおける継続的な技術進歩に牽引され、着実な成長を遂げています。

アンチセンス＆RNAi治療市場分析：

主要市場促進要因：市場促進要因：ドラッグデリバリーシステムの急速な進歩により、細胞に対する治療効果が向上し、標的特異性が高まったこと、遺伝性疾患や慢性疾患の罹患率が高く、最先端の治療法の使用が求められていることなど、強力な技術的要因が市場を牽引しています。

主要市場動向：アンチセンス＆RNAi治療業界の主要動向の1つは、独自の遺伝子プロファイル別の医療の個別化と密接に関連し、患者の転帰の改善を目指すことです。

地理的動向：アンチセンス＆RNAi治療市場分析によると、北米は優れた医療インフラ、高い医療費、友好的な規制環境により、アンチセンス＆RNAi治療市場を独占しています。

競合情勢：この市場は、一流製薬企業やイノベーターといった伝統的な医薬品市場の参入企業が地位を確立しているダイナミックな市場です。競合は、保有技術の特許をめぐる争い、規制当局からのゴーサイン、新たな提携などを左右します。

課題と機会：アンチセンス＆RNAi治療市場調査報告書によると、この業界の大きな課題は、RNAiとアンチセンス別の治療法の開発と管理にかかる高いコストと複雑さです。後者はまた、未治療の遺伝性疾患のブレークスルーをもたらすイノベーションと低コスト創薬の拠点へとこのセクターを変貌させるため、機会でもあります。

アンチセンス＆RNAi治療市場動向：

ドラッグデリバリーシステムの技術進歩

この市場において、主要促進要因のひとつはドラッグデリバリー法の開発が続いていることです。これらの技術により、RNA分子をクリーンかつ効率的に、分解を回避するパターンで関連細胞に送達できるようになり、その結果、治療効果が向上しました。例えば、脂質ナノ粒子とコンジュゲート技術により、アンチセンス・オリゴヌクレオチドやsiRNAの、以前はごくわずかだった細胞への取り込みとバランスが可能になりました。これは、特にがん、疾患、ウイルス感染において重要である、治療が特定のヒト物質を標的とするのに適している類似性の程度を高めつつ、送達を増加させるものです。アンチセンス＆RNAi治療市場予測では、これらの治療法は相当な研究の注目を集め、財政的な投資も行われるであろうことを示しています。例えば、ノバルティスは2023年7月にDTx Pharma社を買収したが、同社は神経科学を適応症とする短鎖干渉性RNA療法に注力しているバイオテクノロジー企業です。同様に、こうした買収は市場の展望を明るいものにしています。

遺伝性疾患と慢性疾患の増加

大衆の間で遺伝性疾患や慢性疾患の発生が加速していることが、アンチセンス＆RNAi治療市場の成長を大きく支えています。ハンチントン病、ある種のがん、広範な遺伝性遺伝性疾患は、効率的な治療法がほとんどない流行性疾患のほんの一例に過ぎず、アンチセンス＆RNAi治療の需要を生み出しています。これとともに、アンチセンスとRNAi治療の選択肢は、病気の原因となる遺伝子の抑制剤の候補として新たな道を記載しています。一方では、この新薬は臨床応用される可能性が高いです。もう一方では、特定の遺伝子を標的とする能力を持つことで、従来の薬理学的手法では対処不可能な状態の患者に対する新たな治療手段となります。このことは、新たなバイオ医薬品研究開発プロジェクトへの継続的な投資の必要性を明確にします。

新規治療に対する支援的な規制環境

アンチセンス＆RNAi治療の需要は、規制環境の支援によって後押しされています。例えば、2023年10月、食品医薬品局の希少製品開発局は、希少疾患や病態に関する自然史研究の実施費用を支援するための2024会計年度の資金提供を発表しました。このRFAは、「希少疾患や病態を持つ患者の利益のために、科学的厳密性と協力を促進する」ことを目的としています。さらに、FDAやEMAのような世界の保健当局は、RNAiやアンチセンス技術を含むあらゆる新しい治療法に対して、より迅速な審査プロセスを導入しています。一方、希少疾病用医薬品（オーファンドラッグ）ステータス、早期承認、優先審査バウチャーといった規制上の優遇措置は、製薬会社にアンチセンスやRNAi療法の開発に力を入れるインセンティブを与えるため、さらに重要性を増しています。

アンチセンス＆RNAi治療市場セグメンテーション：

IMARC Groupは、市場の各セグメントにおける主要動向の分析と、2024～2032年の世界、地域、国レベルの予測を提供しています。当レポートでは、市場を技術、投与経路、用途に基づいて分類しています。

技術別内訳

アンチセンス＆RNAi治療市場シェアの大半を占めるアンチセンスRNA

本レポートでは、技術別に市場を詳細に区分・分析しています。これにはRNA干渉（siRNA、miRNA）、アンチセンスRNAが含まれます。アンチセンス＆RNAi治療市場レポートによると、アンチセンスRNAが最大のセグメントを占めています。

アンチセンスRNA技術は、その成熟した手法と臨床応用の最も長い歴史により、アンチセンス＆RNAi治療市場のリーダーです。アンチセンスRNAは、特定のmRNA配列に付着した合成RNA分子に基づいて作用し、疾患の原因となる標的遺伝子を遮断します。また、遺伝病からがんを含む様々な慢性疾患まで、幅広い応用が可能であることから、アンチセンスRNAはそのリーダー的地位を確立しています。これとは別に、他のRNAi技術とは異なり、リーダーはすでに2年間も広く使用されてきたため、研究や作用機序の開発、送達の開発に大きな資源を投入することができました。さらに、いくつかのアンチセンス治療はすでにFDAに登録され、RNAi技術市場に登場しています。これらすべての要因が、最も大きなシェアを持つ安定したドリルを確保することに貢献しています。さらに、アンチセンスのサブフィールドでは、すでに申請済みの有望な薬剤の増殖が観察されます。このように、この技術はRNAベースの治療市場をリードし、このセグメントでのブレークスルーの基礎を築いています。

投与経路別内訳

肺投与が業界最大シェアを占める

アンチセンス＆RNAi治療市場レポートでは、投与経路別の市場の詳細な区分と分析も行っています。これには静脈内投与、皮下投与、髄腔内投与、肺投与、腹腔内投与、その他が含まれます。同レポートによると、肺送達が最大のアンチセンス＆RNAi治療市場シェアを占めています。

アンチセンス＆RNAi治療市場では、投与経路では肺投与がリードしています。呼吸器疾患の治療に直接利用されるなど、いくつかの正当な理由があり、局所的な投与が効果を著しく高める。このように、肺にアクセスして治療を運ぶことができることは、呼吸器合胞体ウイルスや肺動脈性肺高血圧症などの疾患の治療や、肺がんへの直接的な治療に有効です。これにより、疾患部位への溶液の高濃度投与が可能になり、全身への投与が制限されるため、副作用が少なく、患者のアドヒアランスが向上し、治療効果が全体的に向上しました。さらに、肺組織への効率的なドラッグデリバリーを可能にする革新的な吸入器やソリューションも重要な側面です。増大する負荷のため、治療を可能な限り効果的で的を絞ったものにしなければならないというプレッシャーがあります。したがって、肺への送達はRNAi技術市場の主要開発の焦点となり、全体的な投資と技術革新のクォータを方向づける。

用途別内訳

本レポートでは、市場を用途別に詳細に区分・分析しています。これには、腫瘍学、心血管疾患（CVDs）、呼吸器疾患、腎疾患、神経変性疾患、遺伝性疾患、感染症、その他が含まれます。

地域別内訳

北米が市場をリードし、最大のアンチセンス＆RNAi治療市場シェアを占める

本レポートでは、北米（米国、カナダ）、アジア太平洋（中国、日本、インド、韓国、オーストラリア、インドネシア、その他）、欧州（ドイツ、フランス、英国、イタリア、スペイン、ロシア、その他）、ラテンアメリカ（ブラジル、メキシコ、その他）、中東アフリカを含む主要地域市場についても包括的に分析しています。同レポートによると、アンチセンス＆RNAi治療の最大地域市場は北米です。

北米はアンチセンス＆RNAi治療市場で最大の地域セグメントです。この優位性は、主にこの地域の成熟したバイオテクノロジーと製薬研究のインフラによるものです。さらに、各国政府やその他の世界の保健組織からのかつてない支援により、アンチセンスとRNAi治療プラットフォームの進歩に必要な研究と高度開発のための環境が整っています。アンチセンス＆RNAi治療市場分析によると、この地域にはバイオテクノロジーや製薬の大手企業が数社存在し、激しい競争を生み出してイノベーションを促進しているため、開発機会や製品上市が加速しています。さらに、北米の積極的な規制環境、FDAの例外的な参加は、いくつかの遺伝性疾患や慢性疾患に対する多くのRNAベースの医薬品を迅速に承認しており、RNAベースの治療市場を支えています。さらに、同地域ではがんや遺伝性疾患を含む対象疾患の有病率が高く、アンチセンス＆RNAi治療の需要を生み出しています。このように、北米は技術開拓における支配的な参入企業として、またRNAベースの治療製品の主要市場として、アンチセンス＆RNAi治療市場をリードしています。

本レポートで扱う主要質問

• 世界のアンチセンス＆RNAi治療市場の市場規模は？
• 2024～2032年における世界のアンチセンス＆RNAi治療市場の予想成長率は？
• 世界のアンチセンス＆RNAi治療市場を牽引する主要因は何か？
• 世界のアンチセンス＆RNAi治療市場に対するCOVID-19の影響は？
• 世界のアンチセンス＆RNAi治療市場の技術別内訳は？
• 世界のアンチセンス＆RNAi治療市場の投与経路別の内訳は？
• 世界のアンチセンス＆RNAi治療市場の主要地域は？
• 世界のアンチセンス＆RNAi治療市場における主要参入企業/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界のアンチセンス＆RNAi治療市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：技術別

• RNA干渉
  • 市場動向
  • 主要セグメント
    • siRNA
    • マイクロRNA
  • 市場予測
• アンチセンスRNA

第7章 市場内訳：投与経路別

• 静脈内投与
• 皮下投与
• 脊髄内経路
• 肺からの供給
• 腹腔内注射
• その他

第8章 市場内訳：用途別

• 腫瘍学
• 心血管疾患（CVD）
• 呼吸器疾患
• 腎臓疾患
• 神経変性疾患
• 遺伝性疾患
• 感染症
• その他

第9章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場動向
  • 市場内訳：国別
  • 市場予測

第10章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第13章 価格分析

第14章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Alnylam Pharmaceuticals Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals Inc.
  • Benitec Biopharma Ltd.
  • Bio-Path Holdings Inc.
  • Dicerna Pharmaceuticals Inc.（Novo Nordisk A/S）
  • Ionis Pharmaceuticals Inc.
  • OliX Pharmaceuticals Inc.
  • Phio Pharmaceuticals Corp.
  • Sarepta Therapeutics Inc.
  • Silence Therapeutics
  • Sirnaomics Inc.

List of Figures

• Figure 1: Global: Antisense & RNAi Therapeutics Market: Major Drivers and Challenges
• Figure 2: Global: Antisense & RNAi Therapeutics Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 4: Global: Antisense & RNAi Therapeutics Market: Breakup by Technology (in %), 2023
• Figure 5: Global: Antisense & RNAi Therapeutics Market: Breakup by Route of Administration (in %), 2023
• Figure 6: Global: Antisense & RNAi Therapeutics Market: Breakup by Application (in %), 2023
• Figure 7: Global: Antisense & RNAi Therapeutics Market: Breakup by Region (in %), 2023
• Figure 8: Global: Antisense & RNAi Therapeutics (RNA Interference) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 9: Global: Antisense & RNAi Therapeutics (RNA Interference) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 10: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 11: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 12: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 13: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 14: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 15: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 16: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 17: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 18: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 19: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 20: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 21: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 22: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 23: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 24: Global: Antisense & RNAi Therapeutics (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 25: Global: Antisense & RNAi Therapeutics (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 26: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 27: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 28: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 29: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 30: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 31: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 32: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 33: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 34: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 35: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 36: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 37: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 38: Global: Antisense & RNAi Therapeutics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 39: Global: Antisense & RNAi Therapeutics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 40: North America: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 41: North America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 42: United States: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 43: United States: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 44: Canada: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 45: Canada: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 46: Asia-Pacific: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 47: Asia-Pacific: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 48: China: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 49: China: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 50: Japan: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 51: Japan: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 52: India: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 53: India: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 54: South Korea: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 55: South Korea: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 56: Australia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 57: Australia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 58: Indonesia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 59: Indonesia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 60: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 61: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 62: Europe: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 63: Europe: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 64: Germany: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 65: Germany: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 66: France: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 67: France: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 68: United Kingdom: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 69: United Kingdom: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 70: Italy: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 71: Italy: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 72: Spain: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 73: Spain: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 74: Russia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 75: Russia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 76: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 77: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 78: Latin America: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 79: Latin America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 80: Brazil: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 81: Brazil: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 82: Mexico: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 83: Mexico: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 84: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 85: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 86: Middle East and Africa: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 87: Middle East and Africa: Antisense & RNAi Therapeutics Market: Breakup by Country (in %), 2023
• Figure 88: Middle East and Africa: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 89: Global: Antisense & RNAi Therapeutics Industry: SWOT Analysis
• Figure 90: Global: Antisense & RNAi Therapeutics Industry: Value Chain Analysis
• Figure 91: Global: Antisense & RNAi Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Antisense & RNAi Therapeutics Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Technology (in Million US$), 2024-2032
• Table 3: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
• Table 4: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Application (in Million US$), 2024-2032
• Table 5: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 6: Global: Antisense & RNAi Therapeutics Market: Competitive Structure
• Table 7: Global: Antisense & RNAi Therapeutics Market: Key Players

The global antisense & RNAi therapeutics market size reached US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.25% during 2024-2032. The market is experiencing steady growth driven by the increasing prevalence of genetic and chronic diseases globally necessitates innovative treatments, supportive regulatory environments across major markets to expedite the approval and commercialization of new therapies, and continuous technological advancements in drug delivery systems.

Antisense & RNAi Therapeutics Market Analysis:

Major Market Drivers: The market is driven by powerful technological drivers such as rapid advancements in drug delivery systems, which increased therapeutic impact on cells and targeting specificity, and a high incidence of genetic disorders and chronic diseases, which requires the use of cutting-edge therapeutic modalities.

Key Market Trends: One of the major antisense & RNAi therapeutics industry trends is its tight association with the personalization of medicine based on unique genetic profiles and aimed at improving patient outcomes.

Geographical Trends: According to the antisense & RNAi therapeutics market analysis, North America dominates the market for Antisense & RNAi Therapeutics due to its excellent healthcare infrastructure, high healthcare spending, and friendly regulatory environment.

Competitive Landscape: This is a dynamic market with a pool of traditional drug market players such as top pharmaceutical companies and innovators that have established themselves. The competitive space will have to determine the battle for patents of owned technologies, achieving the green light from the regulatory authorities, and making new collaborations.

Challenges and Opportunities: The antisense & RNAi therapeutics market research report shows that the industry's major challenge is the high cost and complexity of developing and managing RNAi and antisense-based therapies. The latter is also an opportunity since it will transform the sector into loci of innovation and low-cost drug discovery resulting in breakthroughs in untreated genetic diseases.

Antisense & RNAi Therapeutics Market Trends:

Technological advancements in drug delivery systems

In this market, one of the major drivers is the continuing developments of drug delivery methods. These technologies allow RNA molecules to be delivered to relevant cells cleanly and efficiently, in a pattern that avoids degradation and hence provided enhanced efficacy in terms of therapy. For example, lipid nanoparticles and conjugate technologies enabled the previously negligible cellular uptake and balance of antisense oligonucleotides or siRNA. It increases delivery while enhancing the degree of similarity in which therapeutics are suitable to target specific human material, which is critical in cancer, disorders, and viral infections, among other things. The antisense & RNAi therapeutics market forecast indicates that these treatments will gain substantial research attention and financial investment. For instance, Novartis acquired DTx Pharma in July 2023, which is a biotechnology company concentrating on short-interfering RNA therapy for neuroscience indications. Similarly, these acquisitions are creating a positive market outlook.

Increasing prevalence of genetic disorders and chronic diseases

The accelerating incidences of genetic and chronic diseases among the masses is significantly supporting the antisense & RNAi therapeutics market growth. Huntington's, certain types of cancer, and a wide range of hereditary genetic conditions are just a few examples of prevalent illnesses with few efficient treatments, which create demand for antisense & RNAi therapeutics. Along with this, Antisense and RNAi treatment options provide a new avenue as candidate disease-predisposing genes' repressors. On one hand, the new drugs have the best prospects of being included in clinical practice. On the other - by having the ability to target specific genes, they represent a new treatment modality for patients with conditions that are currently unmanageable using conventional pharmacological methods. This, in turn, generates a clear need for continued investment in new biopharmaceutical R&D projects.

Supportive regulatory environment for novel therapies

The antisense & RNAi therapeutics demand is impelled by the supportive regulatory environment. For instance, in October 2023, The Food and Drug Administration's Office of Orphan Products Development announced the availability of funds for fiscal year (FY) 2024 to help underwrite the costs of conducting natural history studies on rare diseases and conditions. The stated goal of this RFA is "to advance scientific rigor and collaboration for the benefit of patients with rare diseases or conditions." In addition, global health authorities, such as the FDA and EMA, are introducing faster review processes for any new therapies, inclusive of RNAi and antisense technology. Meanwhile, regulatory incentives like orphan drug status, accelerated approval, and priority review vouchers gain even more relevance since they give pharmaceutical companies even more incentive to put effort into the development of antisense and RNAi therapies.

Antisense & RNAi Therapeutics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on technology, route of administration and application.

Breakup by Technology:

RNA Interference

siRNA

miRNA

Antisense RNA

Antisense RNA accounts for the majority of the antisense & RNAi therapeutics market share

The report has provided a detailed breakup and analysis of the market based on the technology. This includes RNA Interference(siRNA, and miRNA), and Antisense RNA. According to the antisense & RNAi therapeutics market report, Antisense RNA represented the largest segment.

Antisense RNA technology is the leader in the Antisense & RNAi Therapeutics market due to its mature methodology and the longest history of clinical application. Antisense RNA acts based on synthetic RNA molecules adhering to specific mRNA sequences, and it results in the blockade of target genes responsible for disease. In addition, the broadest possible range of applications from genetic pathologies to chronic diseases of various origins, including cancer, primarily has ensured its leader position. Apart from this, unlike other RNAi technologies, the leaders have already spent up to two years of widespread use, which allowed the investment of large resources in research and developing mechanisms of action and delivery. Moreover, some antisense therapeutic agents are already on the RNAi technology market with active FDA registration, which ultimately confirms their effectiveness and encourages further investment. All these factors contribute to ensuring a steady drill with the most significant share; even more, promising drugs already filed to proliferation can be observed in the antisense subfield. Thus, this technology leads the RNA based therapeutics market and lays the foundation for breakthroughs in this field.

Breakup by Route of Administration:

Intravenous Route

Subcutaneous Route

Intrathecal Route

Pulmonary Delivery

Intraperitoneal Injection

Others

Pulmonary delivery holds the largest share of the industry

A detailed breakup and analysis of the market based on the route of administration have also been provided in the antisense & RNAi therapeutics market report. This includes intravenous route, subcutaneous route, intrathecal route, pulmonary delivery, intraperitoneal injection, and others. According to the report, pulmonary delivery accounted for the largest antisense & RNAi therapeutics market share.

In the Antisense & RNAi therapeutics market, pulmonary delivery has taken the lead in terms of administration channels. There are several justifications, including direct utilization in curing respiratory conditions, in which localized delivery significantly increases the effectiveness. Thus, the ability to access the lungs and carry therapeutic agents is effective in treating diseases such as respiratory syncytial virus and pulmonary arterial hypertension as well as directing to lung cancer. It enabled high concentration of the solution on the site of the disease, limited systemic, hence lower side effects, improved patient adherence, and the overall effectiveness of treatment. Moreover, innovative inhalers and solutions that allow efficient drug delivery to lung tissues are also an important aspect. Due to the increasing load, there is pressure to make therapy as effective and targeted as possible. Therefore, pulmonary delivery serves as a key development focus of the RNAi technology market and directs the overall investment and innovation quotas.

Breakup by Application:

Oncology

Cardiovascular Diseases (CVDs)

Respiratory Disorders

Renal Diseases

Neurodegenerative Disorders

Genetic Disorders

Infectious Diseases

Others

The report has provided a detailed breakup and analysis of the market based on the application. This includes oncology, cardiovascular diseases (CVDs), respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest antisense & RNAi therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for antisense & RNAi therapeutics.

North America is the largest regional segment in the Antisense & RNAi therapeutics market. This prominence is primarily due to the region's mature biotechnological and pharmaceutical research infrastructure. Additionally, unprecedented support from various national governments and other global health organizations has created a conducive environment for research and the advanced development required to progress antisense and RNAi therapy platforms. According to the antisense & RNAi therapeutics market analysis, the presence of several leading biotech and pharmaceutical companies in the region, which has created fierce competition and promoting innovation, has accelerated development opportunities as well as product launch. Additionally, North America's proactive regulatory environment, the exceptional participation of the FDA, which has fast-tracked many RNA-based drugs for several genetic and chronic disease conditions, supports the RNA based therapeutics market. Moreover, the high prevalence of target diseases, including cancer and genetic disorders, in the region creates antisense & RNAi therapeutics demand. Thus, North America leads the Antisense & RNAi Therapeutics market, as a dominant player in technology development and also as the primary market for RNA-based therapeutic products.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the antisense & RNAi therapeutics industry include:

Alnylam Pharmaceuticals Inc.

Arbutus Biopharma Corporation

Arrowhead Pharmaceuticals Inc.

Benitec Biopharma Ltd.

Bio-Path Holdings Inc.

Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)

Ionis Pharmaceuticals Inc.

OliX Pharmaceuticals Inc.

Phio Pharmaceuticals Corp.

Sarepta Therapeutics Inc.

Silence Therapeutics

Sirnaomics Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The major players in the market are increasingly involved in research and development to diversify their genetic therapy portfolios. They are actively engaging in strategic partnerships, taking over small biotech companies, or collaborating with academic institutions and R&D centers to capitalize on emerging and disruptive technologies and fast-track drug development. In confluence with this, considering the high costs and development risks, companies make significant investments in clinical trials to guarantee their effectiveness and safety in a wider applications portfolio, especially in AlNM diseases. Collaboration with the regulatory bodies enhances the companies' competitive performance and guides them along the way to bring new drugs faster. This initiative is vital for creating competitive advantages and a positive antisense & RNAi therapeutics market outlook.

Antisense & RNAi Therapeutics Market News:

April 08, 2024: OliX Pharmaceuticals Inc., a leading developer of RNA interfering therapeutics in the treatment area of severe diseases including fibro-inflammatory and metabolic diseases, disclosed that the Company has gotten approval from the Alfred Human Research Ethics Committee to commence the Phase 1 clinical trial of drug candidate OLX75016 (candidate of OLX702A for NASH treatment).

June 21, 2023: Arbutus Biopharma Corporation provided the first data from the empirical study on RNA interference therapy, nucleos(t)ide analogue (NA), and pegylated interferon alfa-2a therapy in patients with chronic hepatitis B virus at the EASL Conference 2023.

Key Questions Answered in This Report

• 1. How big is the global antisense & RNAi therapeutics market?
• 2. What is the expected growth rate of the global antisense & RNAi therapeutics market during 2024-2032?
• 3. What are the key factors driving the global antisense & RNAi therapeutics market?
• 4. What has been the impact of COVID-19 on the global antisense & RNAi therapeutics market?
• 5. What is the breakup of the global antisense & RNAi therapeutics market based on the technology?
• 6. What is the breakup of the global antisense & RNAi therapeutics market based on the route of administration?
• 7. What are the key regions in the global antisense & RNAi therapeutics market?
• 8. Who are the key players/companies in the global antisense & RNAi therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Antisense & RNAi Therapeutics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Technology

• 6.1 RNA Interference
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 siRNA
    • 6.1.2.2 miRNA
  • 6.1.3 Market Forecast
• 6.2 Antisense RNA
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Intravenous Route
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Subcutaneous Route
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Intrathecal Route
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Pulmonary Delivery
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Intraperitoneal Injection
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Application

• 8.1 Oncology
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Cardiovascular Diseases (CVDs)
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Respiratory Disorders
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Renal Diseases
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Neurodegenerative Disorders
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Genetic Disorders
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Infectious Diseases
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast
• 8.8 Others
  • 8.8.1 Market Trends
  • 8.8.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Alnylam Pharmaceuticals Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Arbutus Biopharma Corporation
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Arrowhead Pharmaceuticals Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 Benitec Biopharma Ltd.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Bio-Path Holdings Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
  • 14.3.6 Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 Ionis Pharmaceuticals Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 OliX Pharmaceuticals Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 Phio Pharmaceuticals Corp.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Sarepta Therapeutics Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Silence Therapeutics
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
  • 14.3.12 Sirnaomics Inc.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio